Assays

Not all pap tests are created equal

The BD SurePath™ Liquid-based Pap Test ensures fewer unsatisfactory results than other methods1,2 and increases HSIL+detection,3 leading to fewer missed cases of invasive cervical cancer4

BD SurePath™ Liquid-based Pap Test

Learn more about the BD SurePath™ collection vial and the BD SurePath™ Liquid-based Pap Test

Offering accuracy from collection to result

The BD SurePath™ Liquid-based Pap Test is your trusted partner for reliable sample collection and accurate result reporting

  • The BD SurePath™ collection vial is designed to improve patient care over conventional pap by providing physicians with the convenience of a single-source collection Pap screening and molecular diagnostic testing
  • The BD SurePath™ Liquid-based Pap Test and the BD Onclarity™ HPV Assay provide HPV primary screening, co-testing and cytology primary with ASCUS reflex
  • When used with the BD Totalys™ MultiProcessor, the BD SurePath™ collection vial 2D barcodes allow Positive Sample Identification from collection through cytological and molecular testing, providing confidence in the results
  • The BD SurePath™ Liquid-based Pap Test can be processed according to the throughput and the automation levels needed. BD Totalys™ MultiProcessor or BD PrepMate™ (sample preparation, including cell enrichment), BD Totalys™ SlidePrep (slide preparation and staining) and BD FocalPoint™ GS Imaging System (slide analysis)

sample

Standardized sample collection

accurate

Accurate result reporting

* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916.  2. Fontaine D et al. BMJ Open. 2012;2(2):e000847.  3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279.  4. Rozemeijer K et al. BMJ. 2017;356:j504.  5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174.  6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153.  7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31

Reduce unsatisfactory results

Due to the unique cell enrichment method, the BD SurePath™ Liquid-based Pap Test exhibits lower unsatisfactory rates compared to conventional cytology and the ThinPrep™ Pap Test

  • Unsats represent a missed opportunity for screening and are more often associated with cervical abnormality2

Leading causes of unsatisfactory samples include:1

Insufficient number of squamous cells

With BD SurePath™ Liquid-based Pap Test, the head of the collection device is deposited directly into the BD SurePath™ collection vial, so 100% of the sample is sent to the laboratory – unlike the rinse-and-swirl technique, which can result in an average of 37% of the cells being discarded5

Obscuring blood and inflammation

The BD SurePath™ Liquid-based Pap Test removes debris such as blood, mucus and inflammatory cells, aiding in visualization of diagnostically relevant cells—and reducing patient callbacks.1,7

microscope

100% of cells for the lab

droplet

90% of blood removed from sample1

* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916.  2. Fontaine D et al. BMJ Open. 2012;2(2):e000847.  3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279.  4. Rozemeijer K et al. BMJ. 2017;356:j504.  5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174.  6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153.  7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31

Increase abnormal cell detection

Reduce the risk of missed cases of invasive cervical cancer by choosing the BD SurePath™ Liquid-based Pap Test

  • The BD SurePath™ Liquid-based Pap Test provides a 64.4% increase in HSIL+ detection compared to conventional cytology5,6

people

Higher disease detection rate

magnify

Lower risk of missing disease

  • Using the BD SurePath™ Liquid-based Pap Test as the primary test method was associated with lower cervical cancer rates diagnosed after a normal screening sample compared to conventional cytology or ThinPrep®*4

19%

reduced risk of invasive cervical cancer following a negative sample result compared to conventional cytology4

29%

reduced risk of invasive cervical cancer following a negative sample result compared to ThinPrep®4

* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916.  2. Fontaine D et al. BMJ Open. 2012;2(2):e000847.  3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279.  4. Rozemeijer K et al. BMJ. 2017;356:j504.  5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174.  6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153.  7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31

Improve the continuum of care

The BD SurePath™ Liquid-based Pap Test can help you achieve actionable results and reduce the burden on the lab and health teams

  • Up-front accuracy leads to fewer patient callbacks, which could reduce patient anxiety
  • Fewer unsatisfactory results reduce the need for reprocessing samples and rescheduling patients, thus lessening the burden on the lab and nursing staff
  • The BD SurePath™ ethanol-based preservative is safe for health care professionals and lab personnel & safe for transport and storage

checkmark

Actionable results

nurse

Reduced burden on staff

* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916.  2. Fontaine D et al. BMJ Open. 2012;2(2):e000847.  3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279.  4. Rozemeijer K et al. BMJ. 2017;356:j504.  5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174.  6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153.  7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31

Contact us to discuss how we can support your cervical cancer screening needs.

Contact us

Contact Us